轻度认知障碍的预后:系统性审查和元分析
Simone Salemme1,2, Flavia Lucia Lombardo3, Eleonora Lacorte3
1Department of Biomedical Metabolic and Neural Sciences University of Modena and Reggio Emilia Modena Italy.
Alzheimer's & dementia (Amsterdam, Netherlands)
|March 13, 2025
概括
轻度认知障碍 (MCI) 的预后因环境而异,在临床研究中痴呆转化率较高. 人口研究显示,显著的30%的逆转率,突出需要更好的护理途径.
科学领域:
- 神经学 神经学
- 老年学是一门学科.
- 公共卫生 公共卫生
背景情况:
- 轻度认知障碍 (MCI) 的预后仍然不完全理解,痴呆症转化率有显著的变化.
- 恢复正常认知是MCI人群中日益公认的结果.
研究的目的:
- 综合当前关于轻度认知障碍 (MCI) 预后的证据.
- 在不同的设置中量化转换风险,稳定性和逆转概率.
- 确定影响MCI预后的因素.
主要方法:
- 进行了89项至少3年后续研究的元分析.
- 研究使用了MCI和痴呆症诊断的既定标准.
- 随机效应建模用于评估预后结果;元回归探索异质性.
主要成果:
- 在临床环境中,MCI转换的总体风险为41.5%,在基于人群的研究中为27.0%.
- 在这两种情况下,认知稳定率约为50%.
- 复发率差异很大,在临床研究中为8.7%,在人口研究中为28.2%.
结论:
- 与人口研究相比,在临床环境中痴呆风险更高,逆转的可能性更低.
- 认知稳定是MCI患者的常见结果.
- 开发可持续的护理途径和在不同环境中进行进一步研究至关重要.
关键词:
阿尔茨海默氏症的疾病是阿尔茨海默氏症.在MCI中,MCI是MCI.大脑健康 大脑健康认知能力下降 认知能力下降转换转换转换的情况分权化,去中心化.痴呆症 痴呆症是一种痴呆症.功能能力 功能能力 功能能力这是一个元分析.初级医疗保健是一项主要的医疗保健服务.护理的质量 护理质量逆转 逆转 逆转 逆转可持续性 可持续性的可持续性更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.1K
07:42Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
2.8K
相关概念视频
Cognitive Development During Adulthood
40
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
40
Alzheimer's Disease: Overview
409
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
409
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
88
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
88
Alzheimer's Disease: Treatment
141
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
141
Dementia
82
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
82
